SMOFLipid ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 1 |
96. Crohn disease
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03773237 (ClinicalTrials.gov) | December 31, 2018 | 12/11/2018 | Intralipid Versus SMOFlipid in HPN Patients | Randomized Prospective Trial Comparing Intralipid Versus SMOFlipid in New HPN Patients. | Short Bowel Syndrome;Intestinal Fistula;Crohn Disease;Intestinal Obstruction | Dietary Supplement: SMOFLipid;Dietary Supplement: Intralipid | Mayo Clinic | NULL | Active, not recruiting | 18 Years | 75 Years | All | 22 | N/A | United States |